| Literature DB >> 27234982 |
Hui Liu1, Yong-Quan Wu2, Li-Ping Chen1, Xiang Gao3, Hao-Nan Huang1, Fu-Lan Qiu1, Ding-Chang Wu1.
Abstract
BACKGROUND Acinetobacter baumannii is an important nosocomial pathogen which shows a high level of mortality risk. Several papers have reported biofilm formation as a well-known pathogenic mechanism in A. baumannii infections and exceptional antibiotic resistance. The study aims to explore the potential relationships between biofilm-related genes and antimicrobial resistance. MATERIAL AND METHODS Samples from 122 patients with lower respiratory tract infections of A. baumannii were collected at Fujian Longyan First Hospital from January 2013 to September 2014. A. baumannii was isolated from sputum specimens. Biofilm-related genes including abaI, csuE, ompA, and bla-PER1 were analyzed by PCR. The minimum inhibitory concentration method was used to determine the sensitivity of each strain to antibiotics. RESULTS The clinical manifestations of A. baumannii-induced lower respiratory tract infections lacked specificity. Infected patients were most commonly admitted to intensive care units (54.9%) and frequently had chronic obstructive pulmonary disease (27.0%). The detection rates of abaI and csuE were both 59.8%, and those of ompA and bla-PER1 were 100% and 0%, respectively. After genetic testing, antimicrobial resistance to amikacin, ampicillin/sulbactam, and 14 other types of antimicrobials was higher in abaI- and csuE-positive strains than in abaI- and csuE-negative strains (P<0.05). CONCLUSIONS The findings of our study suggest that abaI- and csuE-positive Acinetobacter baumannii strains are associated with a higher incidence of antibiotic resistance in 14 types of antimicrobials.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27234982 PMCID: PMC4913728 DOI: 10.12659/msm.898959
Source DB: PubMed Journal: Med Sci Monit ISSN: 1234-1010
Target gene PCR primer sequences and product lengths.
| Gene | Primer sequence (5′-3′) | Product length | |
|---|---|---|---|
| P1 | GTACAGTCGACGTATTTGTTGAATATTTGGG | 382 bp | |
| P2 | CGTACGTCTAGAGTAATGAGTTGTTTTGCGCC | ||
| P1 | ATGCATGTTCTCTGGACTGATGTTGAC | 976 bp | |
| P2 | CGACTTGTACCGTGACCGTATCTTGATAAG | ||
| P1 | CAATTGTTATCTCTGGAG | 966 bp | |
| P2 | ACCTTGAGTAGACAAACGA | ||
| P1 | ATGAATGTCATTATAAAAGC | 978 bp | |
| P2 | AATTTGGGCTTAGGGCAGAA |
Baseline characteristics of patients with A. baumannii infections.
| Mean/number | Range/rate | |
|---|---|---|
| Gender (male) | 102 | 83.6 |
| Mean age | 64 | (1, 98) |
| Length of hospital stay (day) | 16.5 | (4, 95) |
| Body temperature (admission) | 37.15 | (35.0, 39.6) |
| Body temperature (return samples) | 37.70 | (36.0, 39.1) |
| Body temperature (1 day after infection) | 37.40 | (35.5, 40.2) |
| Body temperature (7 days after treatment) | 37.10 | (36.0, 39.1) |
| WBC (admission) | 11.2 | (2.86, 32.14) |
| WBC (return samples) | 12.46 | (2.77, 29.81) |
| WBC (1 day after infection) | 12.21 | (2.35, 30.81) |
| WBC (7 days after treatment) | 11.25 | (4.94, 26.05) |
| Intensive Care Unit | 67 | 54.9% |
| Respiratory Department | 19 | 15.6 |
| COPD | 33 | 27.0% |
| Cardiovascular disease | 25 | 20.5% |
| Cerebral trauma | 14 | 11.5% |
| Diabetes | 19 | 15.6% |
| Hypertension | 26 | 21.3% |
| Ventilator | 43/60 | 71.67% |
| Tracheotomy | 40/54 | 74.07% |
| Urine tube | 14/42 | 33.33% |
| Venous catheterization | 7/29 | 24.14% |
| Sputum suction | 28/60 | 46.67% |
| Fever | 57 | 46.72% |
| Small shape shadow | 70 | 57.38 |
| Large shape shadow | 40 | 32.79 |
Biofilm-related gene expression.
| Gene | Positive | Positive rate (%) |
|---|---|---|
| 73 | 59.8 | |
| 73 | 59.8 | |
| 122 | 100.0 | |
| 0 | 0.0 |
Differences in abaI and csuE positivity and responses to antimicrobial agents.
| Drug | DRR (n%) | ||||||
|---|---|---|---|---|---|---|---|
| + | − | P | + | − | P | ||
| Amikacin | 53.3 | 80.82 | 12.24 | <0.001 | 78.08 | 16.33 | <0.001 |
| Ampicillin/Sulbactam | 65.6 | 97.26 | 18.37 | <0.001 | 94.52 | 22.45 | <0.001 |
| Cefepime | 65.6 | 98.63 | 16.32 | <0.001 | 93.15 | 24.49 | <0.001 |
| Cefoperazone/Sulbactam | 28.7 | 45.20 | 4.08 | <0.001 | 40.09 | 10.20 | <0.001 |
| Cefotaxime | 63.9 | 97.26 | 14.29 | <0.001 | 93.15 | 10.20 | <0.001 |
| Ceftazidime | 63.9 | 97.26 | 14.29 | <0.001 | 93.15 | 10.20 | <0.001 |
| Ciprofloxacin | 67.2 | 97.26 | 22.45 | <0.001 | 94.52 | 26.53 | <0.001 |
| polymyxin E | 0.0 | 0.00 | 0.00 | >0.05* | 0.00 | 0.00 | >0.05* |
| Gentamicin | 64.8 | 97.26 | 16.33 | <0.001 | 93.15 | 22.45 | <0.001 |
| Imipenem | 60.7 | 95.89 | 8.16 | <0.001 | 91.78 | 14.28 | <0.001 |
| Meropenem | 59.8 | 94.52 | 8.16 | <0.001 | 91.78 | 12.24 | <0.001 |
| Piperacillin/Tazobactam | 61.5 | 95.89 | 18.18 | <0.001 | 91.78 | 16.33 | <0.001 |
| Tetracycline | 70.5 | 95.89 | 32.65 | <0.001 | 94.52 | 34.69 | <0.001 |
| SMZco | 65.6 | 94.52 | 22.45 | <0.001 | 91.78 | 26.53 | <0.001 |
| Levofloxacin | 63.1 | 95.89 | 14.26 | <0.001 | 93.15 | 18.37 | <0.001 |
DRR – drug resistance rate.
Associations between specific drug resistance rates and abaI and csuE positivity after adjustment for various factors.
| Drug | Adjusted odds ratio for | 95% CI for | P value for | Adjusted odds ratio for | 95% CI for | P value for |
|---|---|---|---|---|---|---|
| Amikacin | 41.57 | 14.03–123.17 | <0.001 | 15.84 | 5.82–43.15 | <0.001 |
| Ampicillin | 741.65 | 38.33–14349.88 | <0.001 | 89.71 | 17.81–451.83 | <0.001 |
| Cefepime | 3466.57 | 44.60–269445.75 | <0.001 | 132.66 | 15.57–1130.04 | <0.001 |
| Sulbactam | 102.99 | 11.81–898.31 | <0.001 | 20.06 | 5.07–79.28 | <0.001 |
| Cefotaxime | 167.96 | 14.72–1916.05 | <0.001 | 76.66 | 10.07–583.30 | <0.001 |
| Ceftazidime | 181.58 | 31.77–1037.97 | <0.001 | 142.71 | 21.51–946.93 | <0.001 |
| Ciprofloxacin | 107.67 | 19.29–600.89 | <0.001 | 81.78 | 15.72–425.44 | <0.001 |
| Gentamicin | 224.19 | 33.47–1501.67 | <0.001 | 193.38 | 20.88–1791.48 | <0.001 |
| Imipenem | 272.09 | 46.87–1579.63 | <0.001 | 316.75 | 30.33–3308.09 | <0.001 |
| Meropenem | 269.92 | 46.49–1567.26 | <0.001 | 284.59 | 29.22–2772.08 | <0.001 |
| Piperacillin | 511.61 | 49.60–5276.73 | <0.001 | 191.58 | 22.62–1622.41 | <0.001 |
| Tetracycline | 31.35 | 8.15–120.54 | <0.001 | 32.87 | 8.57–126.02 | <0.001 |
| SMZco | 60.51 | 15.34–238.79 | <0.001 | 35.65 | 10.07–126.24 | <0.001 |
| Levofloxacin | 267.31 | 34.07–2097.17 | <0.001 | 138.57 | 22.46–855.06 | <0.001 |
CI – confidence interval. Adjusted: gender, mean age, department, ventilator, tracheotomy, cardiovascular disease, and diabetes.